Investment analysts at StockNews.com initiated coverage on shares of Aethlon Medical (NASDAQ:AEMD – Get Free Report) in a research note issued to investors on Sunday. The firm set a “sell” rating on the medical equipment provider’s stock.
Separately, HC Wainwright reaffirmed a “buy” rating and set a $7.00 target price on shares of Aethlon Medical in a research note on Friday, November 15th.
Read Our Latest Stock Report on Aethlon Medical
Aethlon Medical Stock Up 4.9 %
Aethlon Medical Company Profile
Aethlon Medical, Inc, a medical therapeutic company, focuses on developing products to treat cancer and life-threatening infectious diseases in the United States. It develops Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses and use in organ transplantation.
Read More
- Five stocks we like better than Aethlon Medical
- 3 Monster Growth Stocks to Buy Now
- Vertiv’s Cool Tech Makes Its Stock Red-Hot
- What is the Dow Jones Industrial Average (DJIA)?
- MarketBeat Week in Review – 11/18 – 11/22
- How to Invest in the Best Canadian Stocks
- 2 Finance Stocks With Competitive Advantages You Can’t Ignore
Receive News & Ratings for Aethlon Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aethlon Medical and related companies with MarketBeat.com's FREE daily email newsletter.